Vakiliamini Mazyar, Daryoushi Hooman, Babai Homa, Chegene Lorestani Roya, Rostamian Mosayeb, Akya Alisha, Habibi Reza, Ghadiri Keyghobad
Department of Pediatrics, Clinical Research Development Center, Imam Khomaini and Mohammad Kermanshahi Hospitals, Kermanshah University of Medical Sciences, Kermanshah, Iran.
Department of Pediatrics, Clinical Research Development Center, Imam Reza Hospital, Kermanshah University of Medical Sciences, Kermanshah, Iran.
Glob Pediatr Health. 2023 Jan 29;10:2333794X231152116. doi: 10.1177/2333794X231152116. eCollection 2023.
The prevalence of patent ductus arteriosus (PDA) in preterm infants is high. There is little information about the therapeutic effect and safety of rectal acetaminophen in the treatment of PDA. We aimed to compare the therapeutic effect and safety of oral and rectal acetaminophen on PDA in preterm infants. This study was a single-blind randomized clinical trial using 40 preterm infants. The cases were hospitalized in the neonatal intensive care unit of Mohammad Kermanshahi and Imam Reza hospitals of Kermanshah. Subjects were randomly divided into 2 groups, the first group was treated with oral acetaminophen and the second group was treated with rectal acetaminophen. The presence of PDA and response to treatment was assessed based on pre- and post-treatment echocardiographic criteria. The likelihood of complications or prohibition of acetaminophen use was assessed with paraclinical tests before and after treatment. The neonates were in the age range of 30 to 35 weeks. Twenty-one cases (52.5%) were boys and 19 cases (47.5%) were girls. Two cases in the oral-acetaminophen group and 1 case in the rectal-acetaminophen group needed the second round of treatment. There was no difference between the success of treatment and the type of treatment. The study showed that there was no difference between PDA treatment of preterm infants with oral and rectal acetaminophen. Also, no side effects were observed in treatment with any of the treatments. Therefore, it could be suggested that in infants who are intolerant to oral acetaminophen, the rectal form can be used.
早产儿动脉导管未闭（PDA）的患病率很高。关于直肠用对乙酰氨基酚治疗PDA的疗效和安全性的信息很少。我们旨在比较口服和直肠用对乙酰氨基酚治疗早产儿PDA的疗效和安全性。本研究是一项单盲随机临床试验，纳入了40例早产儿。这些病例在克尔曼沙阿的穆罕默德·克尔曼沙希医院和伊玛目·礼萨医院的新生儿重症监护病房住院。研究对象被随机分为两组，第一组接受口服对乙酰氨基酚治疗，第二组接受直肠用对乙酰氨基酚治疗。根据治疗前后的超声心动图标准评估PDA的存在情况和治疗反应。通过治疗前后的辅助检查评估使用对乙酰氨基酚出现并发症或禁忌的可能性。这些新生儿的年龄在30至35周之间。21例（52.5%）为男孩，19例（47.5%）为女孩。口服对乙酰氨基酚组有2例和直肠用对乙酰氨基酚组有1例需要第二轮治疗。治疗成功率和治疗类型之间没有差异。研究表明，口服和直肠用对乙酰氨基酚治疗早产儿PDA没有差异。此外，任何一种治疗方法均未观察到副作用。因此，可以建议，对于不耐受口服对乙酰氨基酚的婴儿，可以使用直肠剂型。
